About US
Contact us
-
Exports to U.S. to power Indian drugmaker growthThe market forIndiandrugmakers is looking good. Growth this year could reach 20% as exports to the U.S. are driving sales, a report from India Ratings says. "Of the export markets, Indian pharma will2013/2/4
-
U.S. finally gets payment rule publishedIt is 15 months overdue and it will be more than a year before information is public, but at last the government has set out its rule for how it will publishpaymentsfrom drugmakers to doctors. Drug a2013/2/4
-
Merck has to trim outlook as pipeline poops outMerckCEOKenneth Fraziertoday had to give shareholders the bad news and then he had to follow that up with the really bad news. Profit fell 7.3% in the fourth quarter as generics ate the lunch of its2013/2/1
-
OTC plant bites Novartis' reputation againThe closed Novartis ($NVS) consumer products plant in Lincoln, NE, that has besmirched the drug giant's reputation and frustratedCEO Joseph Jimenezhas bitten the company again. This time Novartis ack2013/2/1
-
Sanofi nabs FDA approval for Kynamro, despite safety concernsThe FDA came through with an approval for Kynamro, a treatment for a rare form of high cholesterol from Sanofi's ($SNY)Genzymeunit. But the agency's blessing came with some strings attached: Four post2013/1/31
-
EU enforcers accuse J&J, Novartis of delaying fentanyl genericJohnson & Johnson ($JNJ) and Novartis ($NVS) are the latest pharma companies to feel the ire of EU antitrust regulators.European Commissionofficials have accused the two drugmakers of delaying a g2013/1/31
-
FDA approves Takeda diabetes drug after long waitTakeda Pharmaceutical Company has received approval from the US Food and Drug Administration for Nesina, plus two combinations of the drug, as treatments for type 2 diabetes. Nesina, whose generic na2013/1/30
-
Pfizer's radical R&D cutbacks to continue in 2013Pfizer ($PFE) may be a bit behind schedule, but it's on track to hack its R&D budget to the $6.5 billion-to-$7 billion target laid out in a radical restructuring plan. The company's research spend2013/1/30
-
FDA advisory panel backs limits on painkiller scriptsThe FDA's path through the swamp of painkiller abuse advanced a bit on Friday. An advisory panel backed new controls on hydrocodone drugs, including cough medications and pain pills. The committee re2013/1/29
-
PsiOxus to develop biodefence vaccineThe US Defence Threat Reduction Agency (DTRA) has granted PsiOxus Therapeutics a multi-million dollar contract to be used for research into biodefence vaccine adjuvants with the aim of enhancing thei2013/1/29